In recent years, the capital market's scrutiny of innovative pharmaceutical companies has deepened. While the HKEX's Chapter 18A rules have opened a financing path for pre-profit biotech firms, the core underlying logic for gaining genuine capital recognition lies in consistently anchoring the certainty of clinical value realization and commercial execution. Against this industry backdrop, a Chinese pharmaceutical company is charting a differentiated course, deeply cultivating the significantly undervalued anti-infective field, and holding multiple blockbuster new drugs, continuously exploring the potential value of this blue ocean market.
On May 6, TENNOR THERAP (Suzhou) Co., Ltd. successfully passed the main board listing hearing of the Hong Kong Stock Exchange and officially commenced its IPO on May 14, with CITIC Securities and ABC International acting as joint sponsors. It is understood that the subscription period for TENNOR THERAP (06872) will close on May 19. The company plans to issue approximately 8.28 million shares, with about 10% for public offering in Hong Kong and 90% for international placement. The offer price is set at HK$75.7 per share, with a board lot size of 50 shares. The net proceeds from the offering are expected to be approximately HK$558 million. The company is anticipated to list on May 22.
**Holding Blockbuster First-in-Class Products, Cultivating the Anti-Infective Blue Ocean Market**
TENNOR THERAP is a biotech company nearing the commercialization stage, focused on discovering, developing, and commercializing differentiated innovative drug products to address unmet clinical needs in the fields of bacterial infections and bacteria metabolism-related diseases.
In TENNOR THERAP's pipeline, TNP-2198 is undoubtedly the most notable star product. This drug is the first and, as of the latest practicable date, the only new molecular entity candidate globally for treating Helicobacter pylori (H. pylori) infection since its discovery in 1982. According to Frost & Sullivan data, H. pylori infection is a highly prevalent disease globally, with a treatment market size of $6.9 billion in 2024, projected to rise to $16.1 billion by 2035. The disease is particularly severe in China, with an infection rate as high as 44%, affecting over 600 million patients. Furthermore, this pathogen is closely associated with the occurrence of gastric cancer.
In this context, TENNOR THERAP's self-developed multi-target conjugate molecule technology platform offers a novel approach to tackling the treatment challenges of H. pylori infection. This technology achieves a fundamental breakthrough at the molecular design level by cleverly conjugating two or more synergistic pharmacophores within a single molecule, enabling simultaneous action on key targets crucial for bacterial survival.
The prospectus shows that TNP-2198 is a stable conjugate drug constructed from a rifamycin pharmacophore and a nitroimidazole pharmacophore. It is designed to be used in combination with amoxicillin and a proton pump inhibitor (PPI) to eradicate H. pylori infection. TNP-2198 and amoxicillin are antibacterial drugs used to eradicate bacteria, while the PPI reduces gastric acid secretion, creating a favorable environment for the antibacterial drugs to work, thereby improving the success rate of eradication. More crucially, this drug significantly reduces the probability of bacteria developing resistance from the source, ensuring long-term effective treatment.
As part of a triple therapy, compared to the current guideline-recommended first-line treatment, bismuth quadruple therapy (BQT), TNP-2198 demonstrates significant advantages in efficacy, safety, and potential patient compliance. Clinical data has already shown impressive results: a Phase III head-to-head trial against BQT conducted in China showed that the TNP-2198 triple therapy (RTT) achieved non-inferiority in the primary analysis (mITT) population (92.0% vs. 87.9%, difference 4.1%; non-inferiority test p<0.0001). Furthermore, in the multidrug-resistant (MDR) subgroup, it demonstrated superiority (89.9% vs. 81.2%; difference 8.7%; superiority test p=0.023), directly validating the leading advantage of its multi-target mechanism in overcoming resistance.
Regarding safety, the incidence of adverse events in the RTT group was significantly lower than in the BQT group, with no serious adverse events reported. Simultaneously, its simpler dosing regimen helps improve patient compliance.
Currently, early clinical data for TNP-2198 was published as a featured article in *The Lancet Infectious Diseases* in 2024, and the Phase III clinical trial results were also published in the same journal in 2026, indicating that its clinical value has garnered widespread attention and recognition from the international academic and industry communities.
Beyond the field of H. pylori infection treatment, TENNOR THERAP has also made significant breakthroughs in treating implant-associated bacterial biofilm infections. Its core product, TNP-2092 injection, is the world's first new molecular entity candidate drug expected to be effective against biofilm infections at clinically achievable doses. Notably, TNP-2092 employs a unique triple-target synergistic mechanism, simultaneously inhibiting RNA polymerase, DNA gyrase, and topoisomerase IV. This not only allows it to overcome traditional antibiotic resistance and enhance bactericidal activity against bacterial biofilms but also significantly reduces the frequency of spontaneous resistance.
Data shows that the global incidence of prosthetic joint infections is projected to increase from 86,400 cases in 2024 to 425,800 cases by 2035. The three-year cumulative infection rate for left ventricular assist devices is approximately 60%, and the one-year mortality rate for infected patients is 5.6 times higher than for uninfected patients, indicating the immense market potential for this product.
**Innovation-Driven Technology, Promising Commercial Prospects**
Looking at the product pipeline, TENNOR THERAP, leveraging its multi-target conjugate molecule technology, has independently developed several multi-target candidate drugs with blockbuster potential. It focuses on therapeutic areas with no or limited treatment options, advancing clinical development in both China and the US, building a matrix of "core products + pipeline reserves," and maximizing the value of its R&D pipeline with a global development strategy to provide sustained momentum for long-term growth.
As of the latest practicable date, the company has established a pipeline of seven innovative programs for treating bacterial infections and bacteria metabolism-related diseases, including one nearing commercialization, two in late-stage clinical development, one in the IND approval stage, and three in the preclinical stage.
Currently, TNP-2198 submitted a New Drug Application (NDA) to China's National Medical Products Administration (NMPA) in August 2025 for its triple therapy (RTT) in combination with amoxicillin and a PPI, which was accepted by the NMPA concurrently. Approval is expected by the end of 2026.
Regarding commercialization preparations, TENNOR THERAP has entered into an exclusive cooperation agreement with Yuanda Life Sciences for the commercialization of TNP-2198. According to the agreement, Yuanda Life Sciences will be responsible for the commercialization and promotion of TNP-2198 in Greater China (excluding Taiwan), leveraging its mature marketing network in gastrointestinal diseases to ensure rapid market uptake post-launch.
Furthermore, to support subsequent commercialization development, the company is progressing with the construction of its own production base, which is expected to be officially operational in 2028.
Meanwhile, given the high prevalence of H. pylori infection in China, the vast patient base, coupled with the efficacy limitations of existing therapies due to antibiotic resistance, provides TNP-2198 with broad market development space.
Beyond domestic commercialization, TENNOR THERAP is also positioned to actively explore the broader global market. As a cutting-edge product in the industry, the company is set to occupy a leading advantage in the H. pylori infection treatment field and possesses the robust capabilities to "go global," with promising prospects for worldwide commercialization.
In addition to the two aforementioned core products, another major product of TENNOR THERAP, the TNP-2092 oral formulation, is the world's first multi-target antibacterial candidate drug for treating gut microbiota metabolism-related diseases, showing potential in the treatment of cirrhosis-related hepatic encephalopathy and diarrhea-predominant irritable bowel syndrome (IBS-D).
Research data indicates that the TNP-2092 oral formulation exhibits an extremely low frequency of spontaneous resistance in *Staphylococcus aureus*, significantly lower than rifaximin. It also shows a similar antibacterial spectrum to rifaximin but possesses superior activity against gut ammonia-producing bacteria and higher selectivity for probiotic strains.
In 2024, hepatic encephalopathy, a severe complication of cirrhosis, affected approximately 9.3 million patients globally. IBS-D is an even more common condition, with a global patient count reaching 489.7 million in 2024. Facing such a large patient population with limited existing treatment options, the TNP-2092 oral formulation has the potential to fill this market gap.
Overall, as the first core product gradually opens up the market, TENNOR THERAP's commercialization pathway is expected to be progressively established, becoming a crucial pillar for the company's explosive growth. The innovation-driven R&D focus on clinical value will also accelerate the development of its pipeline products and the expansion of indications, further raising the company's valuation ceiling.
**Conclusion**
In 2026, the Government Work Report of the National People's Congress and the Chinese People's Political Consultative Conference explicitly included the biopharmaceutical industry in the national sequence of "emerging pillar industries" for the first time, alongside integrated circuits, aerospace, and the low-altitude economy. This move marks a historic elevation of the strategic status of biopharmaceuticals, releasing a clear policy signal to strengthen top-level design and accelerate industrial upgrading, injecting certainty into the industry's long-term development.
Consequently, it can be anticipated that TENNOR THERAP possesses a globally competitive technology platform, has built a systematic R&D echelon through its multi-target conjugate molecule technology, and has core products with vast market potential and clear commercialization paths. The company is poised to form a value realization system driven by both "R&D + commercialization," which will serve as long-term drivers for its performance release.
Based on the potential value of its core products, prior to initiating its Hong Kong IPO, TENNOR THERAP completed seven rounds of financing, attracting several renowned investment institutions including AMR Action Fund, WuXi Fund (an investment fund managed by WuXi AppTec), Yuanhe Origin Capital, Gaotejia Capital, and Northern Light Venture Capital. Additionally, Dr. Xiaodong Wang, founder of BeiGene, serves as a scientific advisor to the company and also holds shares in TENNOR THERAP.
The substantial payoff for innovative pharmaceutical companies often occurs when they cross the R&D cycle, achieve commercial landing, and demonstrate systematic self-sustaining capabilities. Now appears to be an opportune time to invest in the future of TENNOR THERAP.
Comments